Global Finance News
25 Sep 2026, 18:13
Bristol Myers Squibb’s ZENBEXUS Doubles MRD-Negative Complete Response Rate in Phase 3 Myeloma Trial
Bristol Myers Squibb (NYSE: BMY) reported positive Phase 3 EXCALIBER-RRMM results for ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.
At a median follow-up of 15.7 months, the ZENBEXUS-based regimen achieved an MRD-negative complete response rate of 41.1%, compared with 20.7% for daratumumab, bortezomib and dexamethasone. Overall response rates were also higher at 88.9% versus 76.1%, while complete response or better reached 45.9% versus 24.9%.
The benefit was consistent across prespecified subgroups, including patients previously treated with lenalidomide and those whose disease was refractory to lenalidomide. However, the regimen was associated with substantially higher Grade 3/4 neutropenia, at 84.3% versus 11.3%, and more Grade 3/4 infections, although peripheral sensory neuropathy was notably lower than with the comparator regimen.
ZENBEXUS in combination with daratumumab and dexamethasone received accelerated FDA approval in August for adults with multiple myeloma who had received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The progression-free survival portion of the Phase 3 trial remains ongoing.
Bristol Myers Squibb (NYSE: BMY) reported positive Phase 3 EXCALIBER-RRMM results for ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.
At a median follow-up of 15.7 months, the ZENBEXUS-based regimen achieved an MRD-negative complete response rate of 41.1%, compared with 20.7% for daratumumab, bortezomib and dexamethasone. Overall response rates were also higher at 88.9% versus 76.1%, while complete response or better reached 45.9% versus 24.9%.
The benefit was consistent across prespecified subgroups, including patients previously treated with lenalidomide and those whose disease was refractory to lenalidomide. However, the regimen was associated with substantially higher Grade 3/4 neutropenia, at 84.3% versus 11.3%, and more Grade 3/4 infections, although peripheral sensory neuropathy was notably lower than with the comparator regimen.
ZENBEXUS in combination with daratumumab and dexamethasone received accelerated FDA approval in August for adults with multiple myeloma who had received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The progression-free survival portion of the Phase 3 trial remains ongoing.
